In Section C, members will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until illness progression or even the individuals are unable to tolerate the study drugs. 88 These preclinical studies provide paradigms for future clinical trials in AML, and https://cashthvgk.digitollblog.com/31757871/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know